Skip to main content
. Author manuscript; available in PMC: 2018 Feb 15.
Published in final edited form as: Cancer Res. 2017 Jun 19;77(16):4355–4364. doi: 10.1158/0008-5472.CAN-17-0498

Figure 2. PKM1/2 knock-down does not affect c-MYC-induced liver tumorigenesis.

Figure 2

A) Total pyruvate kinase activity measured in normal livers (n=3), c-MYC-shLuc/MCL1 (n=3) and c-MYC-shPKM/MCL1 (n=3) tumors. Data are presented as mean ± SD. Student’s t-test was used; *p <0.05, **p <0.01, ***p <0.001. B) Western blot analysis of glycolytic enzymes and proliferation associated proteins in normal livers, c-MYC-shLuc/MCL1 and c-MYC-shPKM/MCL1 tumors. C) Survival analysis of mice bearing c-MYC-shLuc/MCL1 (n=8) and c-MYC-shPKM/MCL1 (n=7) tumors using Kaplan-Meier survival method. Gross images of both tumors are shown in the right panel.